Drug Profile

PYC 001

Alternative Names: PYC-001

Latest Information Update: 21 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PYC Therapeutics
Class Antisense oligonucleotides; Eye disorder therapies; Morpholines; Peptide drug conjugates
Mechanism of Action OPA1 protein expression stimulants; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

15 May 2025 PYC Therapeutics plans a phase I/II trial for Optic atrophy (Treatment-naive) in Australia (Intravitreous), in June 2025 (NCT06970106)
31 Oct 2024 Phase-I clinical trials in Optic atrophy in Australia (Intravitreous) (NCT06461286)
03 Feb 2023 Discontinued - Preclinical for Diabetic retinopathy in Australia (Intravitreous) (before February 2023) (PYC Therapeutics Pipeline, February 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com